Whalen Wealth Management Inc. decreased its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 89.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,285 shares of the exchange traded fund’s stock after selling 18,778 shares during the period. Whalen Wealth Management Inc.’s holdings in SPDR S&P Biotech ETF were worth $226,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tidemark LLC lifted its holdings in shares of SPDR S&P Biotech ETF by 101.5% during the 3rd quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock valued at $39,000 after buying an additional 199 shares during the last quarter. ORG Partners LLC acquired a new stake in SPDR S&P Biotech ETF in the second quarter valued at approximately $40,000. Quintet Private Bank Europe S.A. bought a new stake in SPDR S&P Biotech ETF in the third quarter worth approximately $40,000. ORG Wealth Partners LLC acquired a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth $44,000. Finally, Waldron Private Wealth LLC acquired a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth $54,000.
SPDR S&P Biotech ETF Trading Up 0.2 %
XBI stock opened at $91.98 on Tuesday. The firm has a market cap of $7.01 billion, a PE ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1 year low of $71.98 and a 1 year high of $105.47. The company has a fifty day simple moving average of $98.83 and a 200 day simple moving average of $96.20.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Capture the Benefits of Dividend Increases
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What is the Hang Seng index?
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.